Skip to content
  • Home
  • Signal News
  • Biopharma Digest
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Regulatory Interactive Calendar
    • Manufacturing Intelligence
  • Contact

Pharminent

 Posted in M&A / Deals

UCB to purchase Neurona and NRTX-1001 for $1.15bn

 April 20, 2026

Pharmaceutical Business Review

The deal value comprises an upfront payment of up to $650m and up to $500m in future milestones.

M&A / DealsNeuroscienceRead full story

Post navigation

MSD secures EC approval for Enflonsia to prevent infant RSV infection →
← Trump backs psychedelics for mental health in new executive order

Categories

© 2026 Pharminent. All rights reserved.

Design by ThemesDNA.com